08:00 , Feb 2, 2015 |  BC Week In Review  |  Company News

Astute, bioMerieux deal

Astute granted bioMerieux semi-exclusive, worldwide rights to develop and commercialize Astute’s NephroCheck test for early risk assessment of acute kidney injury on bioMerieux’s Vidas diagnostic platform. NephroCheck is an immunoassay for insulin-like growth factor (IGF)...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Company News

Ortho-Clinical Diagnostics sales and marketing update

Ortho-Clinical launched the NephroCheck testing system in the U.S. to assess the risk of patients ages 21 years and older developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

NephroCheck test regulatory update

FDA granted 510(k) clearance to Astute's NephroCheck Test System to assess the risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. The product is...
08:00 , Feb 21, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma IGFBP7 A study in cell culture and xenograft mice suggests that the secreted protein IGFBP7 could be useful for treating...